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Recently we confirmed that latent membrane protein 1 (LMP1) encoded by Epstein-Barr virus (EBV) accelerates a newly form
-Jun/Jun B heterodimer, a transcription factor, but little is known about the target gene regulated by it. In this paper, results
hat a c-Jun/Jun B heterodimer induced by LMP1 upregulated cyclin D1 promoters activity and expression, on the contrary, dow
16, and maladjustment of cyclin D1 and p16 expression accelerated progression of cell cycle. Firstly, we found a c-Jun/Jun B h
egulated synchronously and directly cyclin D1 and p16 in the Tet-on-LMP1-HNE2 cell line, in which LMP1 expression is regulated b
ystem. This paper investigated in depth function of the newly forming active c-Jun/Jun B heterodimer, and built new connectio
nvironmental pathogenic factor, signal transduction and cell cycle.
2005 Elsevier B.V. All rights reserved.
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. Introduction
EBV is a ubiquitous human herpesvirus that infects over
0% population of the world. LMP1, which can transform
odent fibroblasts and make nude mice tumorigenic, is con-
idered to be a major oncogenic protein encoded by EBV
Eliopoulos and Young, 1998). LMP1 is an integral mem-
rane protein composed of a short cytoplasmic N-terminus
f 24 amino acids, six transmembrane domains of 162 amino
cids and a cytoplasmic C-terminus of 200 amino acids. The
∗ Corresponding author. Tel.: +86 731 4805448; fax: +86 731 4470589.
E-mail address: ycao98@public.cs.hn.cn (Y. Cao).
1 Present address: Department of Gastroenterology, First Affiliated Hos-
ital, Sun Yat-sen University, Guangzhou 510080, China.
carboxyl terminus comprises two functional domains:
membrane proximal c-terminal activation region-1 (CTA
and the membrane distal CTAR2 (residues 351–386). L
can activate AP1 signal pathway through CTAR2 fuction
gion, thus causing abnormal cell proliferation and phenot
changes (Vogt, 2001).
Recent findings show that roles of c-Jun or Jun B,
portant components of AP1 family, are complex, depe
ing on the cellular context and cell type (Deng and Karin
1993; Mathas et al., 2002; Leaner et al., 2003; Szabo
et al., 2000). c-Jun overexpression makes tumors inva
(Wisdom et al., 1999; Smith et al., 1999), on the other hand
also, triggers apoptosis (Bossy-Wetzel et al., 1997; Wang
al., 1999a). Jun B is always deemed to the inhibitory co
ponent of AP1 transcription factor (Passegue et al., 200),
168-1702/$ – see front matter © 2005 Elsevier B.V. All rights reserved.
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and it can regulate erythroid and myogenic differentiation
(Jacobs-Helber et al., 2002; Chalaux et al., 1998), however,
some findings demonstrate that Jun B promotes carcinogen-
esis (Mao et al., 2003; Robinson et al., 2001).
Further study indicates that Jun B is a negative regulator
of c-Jun (Szabowski et al., 2000; Chiu et al., 1989), and Jun B
represses c-Jun by forming an inactive heterodimer (D ng et
al., 2003). The balance of Jun B with c-Jun activity is involved
in regulating the key steps in the proliferation and differenti-
ation process (Schlingensiepen et al., 1993). However, some
findings show that c-Jun and Jun B cooperatively regulate
some target genes in an AP1-dependant manner, which pro-
motes the cell proliferation and differentiation abnormally
(Mathas et al., 2002; Leaner et al., 2003).
Our study demonstrated in Tet-on-LMP1-HNE2 cell line,
LMP1 triggered a signaling cascade via its CTAR2 bind-
ing TRADD/TRAF2 signaling molecular, activated JNK and
then upregulated AP1 activity including c-Jun and c-fos (Liao
et al., 1999a,b; Deng et al., 2003; Wang et al., 2002). Using
AtlasTM Apoptosis cDNA Expression Array, we found that
LMP1 induced both Jun B and c-Jun in the time- and dose-
dependent manner in Tet-on-LMP1 HNE2 cell line (data not
shown).
More recently, we have proved that LMP1 activates c-Jun
NH2-terminal kinase (JNK), regulates protein expression and































Using AtlasTM human cDNA expression array I (Clon-
tech) detecting normal human nasopharyngeal tissue and na-
sopharyngeal carcinoma, we found cyclin D1 overexpression
in the nasopharyngeal carcinoma at the transcriptional level
(Li et al., 1998; Xie et al., 2000). In the meantime, we proved
cyclin D1 protein expression increased gradually in the
multistage tissue of the simple hyperplasia/metaplasia, atyp-
ical hyperplasia/metaplasia and nasopharyngeal carcinoma
during nasopharyngeal carcinogenesis, strengthening signifi-
cantly especially in the atypical hyperplasia/metaplasia tissue
(data not shown). Further study indicated LMP1 encoded
by EBV regulated cyclin D1, thus led to disorder of prolif-
eration and maladjustment of apoptosis (Zhao et al., 2000,
2001).
On the other hand, point mutation of p16 (Sun et al., 1995)
occurs rarely in the human nasopharyngeal carcinomas, but
there exists frequent inactivation of p16 (Huang et al., 2001;
Baba et al., 2001), or lack (Gulley et al., 1998; Makitie et al.,
2003; Lo et al., 1995), or hypermethylation of its promoters
(Jefferies et al., 2001; Chang et al., 2003; Lo et al., 1996).
Restoration of p16 in nasopharyngeal carcinoma inhibited
significantly tumorigenic potential (Wang et al., 1999b; Lee
et al., 2003). Meanwhile, EBV inhibited p16 expression in
human fetal nasopharyngeal epithelial cells escaping from




























nduces an active c-Jun/Jun B heterodimer formation (Song
t al., 2004). To further study the function of the c-Jun/J
heterodimer, it is crucial to find target gene regula
y it.
To be important, recently, a new direct connection
ound between c-Jun and cyclin D1 related to G1/S ch
oint of cell cycle. c-Jun activated cyclin D1 promoters ac
ty by binding to two AP1-alike sites in cyclin D1 promo
egion in the HeLa cell line (Herber et al., 1994). Jun B and c
un were a pair of antagonistic transcriptional modulator
he ratio of Jun B/c-Jun determined cyclin D1 transcriptio
he early G1 phage and balance of cell cycle. Phosphoryl
f Jun B and c-Jun strengthened their transcriptional act
egulated their dynamic balance, and at last modulate
lin D1 promoters activity, influencing cyclin D1 express
Bakiri et al., 2000).
In the meantime, also, a new direct connection is rec
ound between Jun B and p16, a negative modulator re
o cell cycle. Three AP1-like binding sites were identifie
he mice p16 promoter region. Jun B can activate directly
ranscription through binding to these sites (Passegue an
agner, 2000). Using Domain Architecture Retrieval To
http://www.ncbi.nlm.nih.gov/Structure/Dart/Lexington/
tml/overview.html), we found that Jun B domains betwe
uman and mice are highly homologous (99%), and the
nly an amino acid difference in the basic leucine zipper
ain (bZIP) of Jun B. We further predicted that four puta
P1 bind sites exist in the human p16 promoters using
nformatics (http://www.cbrc.jp/research/db/TFSEARC
tml).These studies above all suggest that cyclin D1 and p16
e adjusted synchronously by the c-Jun/Jun B heterod
nduced by LMP1.
So, based on progress on study of literature and our
one (Song et al., 2004), in this paper, we want to inve
igate in depth whether a c-Jun/Jun B heterodimer ind
y LMP1 could regulate cyclin D1 and p16 synchronou
hich are closely related to cell cycle, and accelerate
ycle progression.
. Materials and methods
.1. Cell culture
HNE2 is EBV-negative, poorly differentiated NPC c
ine. Tet-on-LMP1-HNE2 was constructed by transfec
MP1 expressin plasmid and tet-on system into HNE2
he Tet-on-LMP1-HNE2, LMP1 and tet-on was stably in
rated, the expression of LMP1 will be turned on by te
ycline (Doxycline, Dox). Two cell lines were establish
y Cancer Research Institute, Xiangya School of Medic
entral South University (Liao et al., 1999a,b, 2001). Tet-
n-LMP1-HNE2 cells were cultured in RPMI 1640 medi
GIBCO BRL) containing 100g/ml G418, 50g/ml hy-
romycin and 10% FCS (GIBCO BRL) in a humidified 5
O2 atmosphere at 37◦C. To induce LMP1 expression, ce
ere treated with Dox at 0, 0.006, 0.06, 0.6 and 6.0g/ml,
espectively. In the meanwhile, with 0.6g/ml Dox induc-
ion, cell was collected at the time points of 0, 0.5, 1, 2, 4
2, 18 and 24 h.
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2.2. Protein extraction
After treatment with Dox, the cells were washed with
ice-cold PBS and lysed by 10 min incubation on ice with
lysis buffer (50 mol/ml Tris Cl PH 7.6, 400 mol/ml NaCl,
1 mol/ml EDTA, 1 mol/ml EGTA, 1% NP40, 0.5g/ml le-
upeptin, 0.5g/ml aprotinin, 0.5g/ml pepstatin, 1 mol/ml
PMSF). The lysate was centrifuged for 5 min at 14,000 rpm.
For electrophoresis mobility shift assays (EMSA)
(Andrews and Faller, 1991), nuclear extracts were prepared
by growing cells to confluence, washing them three times
in cold phosphate-buffered saline (PBS), and harvesting
them by scraping. Cells were precipitated in a microcen-
trifuge, rinsed with hypotonic buffer [10 mM HEPES (pH
7.9), 1.5 mM MgCl2, 10 mM KCl], and resuspended in two
pellet volumes of hypotonic buffer. After 5 min on ice, the
suspension was lysed by adding 1l of 5% Nonidet P-40 and
agitated by pipetting through a Pasteur pipette. Nuclei were
then rocked for 30 min at 4◦C to ensure complete lysis with
buffer C [20 mM HEPES (pH 7.9), 20% glycerol, 100 mM
KCl, 0.2 mM EDTA]. Dithiothreitol (DTT) (0.5 mM), 1 mM
phenylmethylsulfonyl fluoride (PMSF), 1g of leupeptin/ml,
1g of aprotinin/ml, 1 mM sodium vanadate, and 20 mM
sodium fluoride were added to each solution just prior to use.




























lined) in p16 promoter region (Bakiri et al., 2000; Passegue
and Wagner, 2000) were predicted by bioinformatics and
synthesized as follows: probe1: 5′-AAAAGTATTAGTCA-
CAGGAAA-3′ (−14 to −23); probe2: 5′-GTCTCATTCT-
GTCACCCAGGC-3′ (−530 to−539); probe3: 5′-CTTCC-
AATGACTCCCTCCCCA-3′ (−1162 to −1171); probe4:
5′-GGGTTTCTGACTTAGTGAACC-3′ (−1380 to−1387).
Universal AP1 Probe (Lee et al., 1987; Briggs et al., 1986) for
positive control and SP1 probe (Briggs et al., 1986; Vallone
et al., 1997) for intrinsic control were also synthesized
as follows: AP1: 5′-TTCCGGCTGACTCATCAAGCG-3′;
SP1: 5′-ATTCGATCGGGGCGGGGCGAGC-3. All probes
as above were synthesized and labeled with biotin at 3′-
terminal by Laboratory of Molecular Technology, SAIC-
Frederick National Cancer Institute, USA.
2.5. Transfection conditions and luciferase assay
Plasmids purification were followed as instruction of QIA-
GEN Plasmid Maxi Kit (Qiagen). Before transfection, cells
were seeded in six-well plates overnight. Transfection was
performed using SuperFect transfection Reagent kit (Qia-
gen). The luciferase activity was detected with luciferase as-
say kit (Promega). The plasmids were used as follows: p16
promoters reporter plasmid was kindly presented by Dr. Pe-


























i ime,.3. Western blotting
One hundred micrograms aliquots of protein lysates w
ixed with the sample buffer and boiled for 5 min. Sam
ere then resolved on 8% polyacrylamide gel contai
DS, and transferred to nitrocellulose membrane (Schle
Schuell) by electro blotting. The membrane was incub
n blocking buffer (TBS containing 5% skim milk and 0.1
ween 20) for 2 h, followed by incubation with prima
ntibody diluted to 1:1000. The membrane was washe
BS containing 0.1% Tween 20. Specifically second
ntibody was detected using peroxidase-conjugated an
t 1:10,000. Relative proteins were detected by supers
hemiluminescence system (ECL, Pierce) followed by e
ure to autoradiographic film. The Nitrocellulose memb
as stripped with stripping buffer and reblotted. LMP1 (c
, DAKO), AP1(D)-G, widely reactive with c-Jun, Jun B a
un D (sc-44-G, Santa Cruz), c-Jun (sc-1694, Santa C
un B (sc-8051, Santa Cruz), a-tubulin (sc-5286, Santa C
16 (sc-759, sc-2037) and cyclin D1 (H-295, Santa Cru
.4. Probes
Two double-stranded probes containing AP1 binding
underlined) in cyclin D1 promoter region (Herber et al.
994) were synthesized as follows: probe1: 5′-AAAAAAT-
AGTCAGAATGGAG-3′ (−929 to−935); probe2: 5′-CA-
CAGTAACGTCACACGGAC-3′ (−45 to −52). Four
ouble-stranded probes containing AP1 binding site (unorter plasmid was kindly provided by Prof. Strauss (Hinz et
l., 1999) and-galactosidase expression plasmid (pRS-
al) was gently provided by Dr. Perkins ND (Chapman an
erkins, 2000).
.6. Electrophoresis mobility shift assay (EMSA) and
uper-EMSA
For EMSA (LightShiftTM Chemiluminescent EMSA K
ierce), 5g of nuclear extract was incubated with 20 fmo
he end-labeled with biotin double-stranded oligonucleo
robes in reaction buffer for 20 min at room temperat
or supershift reactions, the optimal concentration of
ntibody was determined by titration into the EMSA reac
ixture. All antibodies were added at the same concentr
12.5 ng/l) to correspond to the optimal concentrat
f the least potent antibody that showed a discern
upershift. Samples were resolved on a nondenaturin
olyacrylamide 2% glycerol gel, transferred to Biodyn®
Nylon membrane, avidin-HRP to probes and visual
nd quantitated with a PhosphorImager. Transcription fa
P1 bindings sequence was used as a control probe. T
ershift antibodies were used as follows: AP1(D)-G, wid
eactive with c-Jun, Jun B and Jun D (sc-44-G, Santa C
-Jun (sc-1694, Santa Cruz), Jun B (sc-8051, Santa Cr
.7. DNA content assay
Untreated and treated cells were collected, after cult
n the presence or absence of Dox for the indicated t
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rinsed with PBS and suspended in 75% ethanol at−20◦C
overnight. Fixed cells were centrifuged and washed with PBS
twice. For detecting DNA content, cells were soaked in the
dark in 400l PBS containing 50g/ml of PI and 0.1% of
RNase A at 25◦C for 30 min. Stained cells were analyzed by
flow cytometry (model: ELITE, laser wavelength: 488 nm,
power: 15 mW, Beckman–Coulter, USA). The percentage of
cell in G1, S and G2 phases was determined using the MUL-
TYCYCLE software program (PHEONIX).
2.8. Immunocytometry
Cells were washed with PBS and resuspended in 75%
ethanol at−20◦C overnight. Fixed cells were centrifuged,
washed with PBS and treated with 0.25% Triton X-100 in
PBS for 5 min. After the addition of PBS and centrifuga-
tion, the samples were incubated with mouse mAb to hu-
man cyclin D1 (DCS-6 DAKO) or to human p16 (sc-1661,
Santa Cruz) at−4◦C overnight. The antibody was diluted in
PBS containing 1% BSA and applied at a ratio of 0.25g
of mAb/5× 105 cells. After washed with 1% BSA, the cells
were incubated in the dark with FITC-conjugated sheep anti-
mouse IgG (F2266, Sigma) for 30 min. After washed with
1% BSA again, the cells were stained with 50g/ml PI and
0.1% RNase in 400l PBS for 30 min. Cells were analyzed



























Fig. 1. (A) Dose response of Dox induction of LMP1 expression. Tet-on-
LMP1-HNE2 cells were treated with Dox at 0.006, 0.06, 0.6 and 6g/ml,
respectively, as a control without Dox induction, and the whole protein was
extracted. 100g of cellular protein was subjected to electrophoresis on
8% SDS-polyacrylamide gel and Western blot analysis. LMP1 (∼60 kDa) is
identified by probing with a specific antibody described in Section2. Signals
were normalized using expression of-tubulin as control. (B) Time course
of of Dox induction of LMP1 expression. Tet-on-LMP1-HNE2 cells were
treated with Dox at 0.6g/ml. The whole protein was extracted, respectively,
at the time points of 0, 0.5, 1, 2, 4, 8, 12, 18 and 24 h; 100g of cellular
protein was subjected to electrophoresis on 8% SDS-polyacrylamide gel
and Western blot analysis. LMP1 (∼60 kDa) is identified by probing with
a specific antibody described in Section2. Signals were normalized using
expression of-tubulin as control.
TFSEARCH.html). To detect whether the c-Jun/Jun B het-
erodimer combined with p16 promoter region, by Super-
EMSA, results indicated two subunits of c-Jun and Jun B
could both bind to p16 promoter region (sequences of bind-
ing sites: 5′-TTCTGTCACC-3′) (Fig. 3).
3.2. c-Jun/Jun B heterodimer modulated cyclin D1 and
p16 promoters activity as well as their expression with
induction of LMP1
Cyclin D1 luciferase reporter plasmid and-gal expres-
sion plasmid were cotransfected into HNE2 cells and Tet-
Fig. 2. c-Jun/Jun B heterodimer DNA-binding activity in the cyclin D1 pro-
moter region in the Tet-on-LMP1-HNE2 cells treated with 0.6g/ml of Dox
for 12 h. Nuclear extracts were prepared from cells. Gel supershift assays
were performed by initially incubating 5g of nuclear protein with 20 fmol
of 3′biotin-labelled duplex containing a single AP1 binding site for 20 min at
room temperature. Various antibodies (1g) described in Section2 against
either c-Jun or Jun B were then added to the binding reaction mixtures and
the reaction was allowed to proceed for an additional 30 min at room temper-
ature. Universal AP1(D)-G antibody for a positive control is widely reactive
with c-Jun, Jun B and Jun D (sc-44-G, Santa Cruz). Universal AP1 Probe
(Lee et al., 1987; Briggs et al., 1986) is used as a positive control. The spe-
cific supershifted AP1 components are indicated by arrows. Signals were
normalized using binding activity of SP1 as intrinsic control. Two experi-







ometry and Cellquest softward (Becton Dickinson).
. Results
.1. Binding activity of the c-Jun/Jun B heterodimer with
yclin D1 and p16 promoters induced by LMP1
It was found that LMP1 expression by western blot in
et-on-LMP1-HNE2 cells treated with Dox at 0, 0.006, 0
.6, 6.0g/ml, respectively, increased in a dose-depen
anner, reached to peak at 0.6g/ml (Fig. 1A). Thus, cells
ere treated with Dox at 0.6g/ml, and nuclear protein w
xtracted at the time points of 0, 0.5, 1, 2, 4, 8, 12, 18 and
MP1 expression was found to increase in a time-depen
anner (Fig. 1B).
Recent study has proved in the Tet-on-LMP1-HNE2 c
reated with Dox for 12 h at 0.6g/ml, LMP1 can acce
rate effectively c-Jun/Jun B heterodimers formation,
trengthen significantly AP1 DNA-binding activity of the h
rodimers (Song et al., 2004).
Therefore, on the condition, Tet-on-LMP1-HNE2 ce
ere treated with 0.6g/ml Dox for 12 h, and nuclear prote
as extracted. It was found by Super-EMSA two subu
f c-Jun and Jun B could both bind to cyclin D1 promo
egion (sequences of binding sites: 5′-TGAGTCA-3′)
Fig. 2).
In the meanwhile, we predicted that four puta
P1-binding sites exist in the human p16 promo
egion by bioinformatics (http://www.cbrc.jp/research/dinding activity with synthesized probes as described above of the c-Ju
heterodimer in the cyclin D1 promoter region in the Tet-on-LMP1-HN
ells treated with 0.6g/ml of Dox for 12 h. (B) Jun B subunit DNA-bindin
ctivity with synthesized probes as described above of the c-Jun/Jun
rodimer in the cyclin D1 promoter region in the Tet-on-LMP1-HNE2 c
reated with 0.6g/ml of Dox for 12 h.
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on-LMP1-HNE2 cells treated with Dox for 24 h at 0, 0.006,
0.06, 0.6, 6g/ml, respectively. It was found that cyclin D1
luciferase activity increase gradually, compared to 0g/ml,
up to over six times at 6g/ml (∗P < 0.05) (Fig. 4A).Fig. 2.
Fig. 3. c-Jun/Jun B heterodimer DNA-binding activity in the p16 promoter
region in the Tet-on-LMP1-HNE2 cells treated with 0.6g/ml of Dox for
12 h. Nuclear extracts were prepared from cells. Gel supershift assays were
performed by initially incubating 5g of nuclear protein with 20 fmol of
3′-biotin-labelled duplex containing a single AP1 binding site for 20 min at
room temperature. Various antibodies (1g) described in Section2 against
either c-Jun or Jun B were then added to the binding reaction mixtures
and the reaction was allowed to proceed for an additional 30 min at room
temperature. Universal AP1(D)-G antibody for a positive control is widely
reactive with c-Jun, Jun B and Jun D (sc-44-G, Santa Cruz). Universal AP1
Probe (Lee et al., 1987; Briggs et al., 1986) is used as a positive control.
The specific supershifted AP1 components are indicated by arrows. Signals
were normalized using binding activity of SP1 as intrinsic control. Two ex-
periments were performed that showed similar results. (A) c-Jun subunit
DNA-binding activity with synthesized probes as described above of the
c-Jun/Jun B heterodimer in the p16 promoter region in the Tet-on-LMP1-
HNE2 cells with 0.6g/ml of Dox for 12 h (B) Jun B subunit DNA-binding
activity with synthesized probes as described above of the c-Jun/Jun B het-
erodimer in the p16 promoter region in the Tet-on-LMP1-HNE2 cells with
0.6g/ml of Dox for 12 h.
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Fig. 4. (A) Dose response of cyclin D1 luciferase activity in Tet-on-LMP1-
HNE2 cells treated, respectively, with 0, 0.006, 0.06, 0.6, 6g/ml of Dox,
as a control in HNE2 cells. Cyclin D1 luciferase reporter plasmid and-gal
expression plasmid were cotransfected into HNE2 cells and Tet-on-LMP1-
HNE2 cells treated with Dox for 24 h at 0, 0.006, 0.06, 0.6, 6g/ml, respec-
tively. Cells were extracted in 100l of lysis buffer, and cyclin D1 activity
was measured as described in Section2. The level of cyclin D1 activity
increased evidently compared to that of without Dox induction (∗P < 0.05,
compared to 0g/ml). Results are means of at least three experiments, and
Error bars indicate 1 standard deviation from the mean. The expression plas-
mid of -gal (pRSV-gal) as an intrinsic control. (B) Dose response of Dox
induction of cyclin D1 expression. Tet-on-LMP1-HNE2 cells were treated
with 0, 0.006, 0.06, 0.6, 6g/ml of Dox, as a control without Dox induction
at every dose. Cellular protein (100g) was subjected to electrophoresis on
8% SDS-polyacrylamide gel and Western blot analysis. Cyclin D1 is identi-
fied by probing with a specific antibody described in Section2. Signals were
normalized using expression of-tubulin as control. (C) Time course of cy-
clin D1 protein expression in the Tet-on-LMP1-HNE2 cells treated with with
0.6g/ml of Dox, as a control without Dox induction at every time point.
Cells were treated with 0.6g/ml of Dox. 100g of cellular protein was
subjected to electrophoresis on 10% SDS-polyacrylamide gel and Western
blot analysis. Cyclin D1 is identified by probing with a specific antibody de-
scribed in Section2. Signals were normalized using expression of-tubulin
as control.
Based on the c-Jun/Jun B heterodimer binding with cyclin
D1 promoters and regulating its activity with the induction
of LMP1, cyclin D1 protein expression was further studied.
The results demonstrated it increased in a dose-dependent
manner (Fig. 4B).
Our recent study has confirmed LMP1 protein expression
























ig. 5. (A) Dose response of p16 luciferase activity in Tet-on-LMP1-HNE2
ells were treated, respectively, with 0, 0.006, 0.06, 0.6, 6g/ml of Dox, as a
ontrol in HNE2 Cells. p16 luciferase reporter plasmid and-gal expression
lasmid were cotransfected into HNE2 cells and Tet-on-LMP1-HNE2 cells
reated with Dox for 24 h at 0, 0.006, 0.06, 0.6, 6g/ml, respectively. Cells
ere extracted in 100l of lysis buffer, and p16 activity was measured as de-
cribed in Section2. The level of p16 activity decreased evidently compared
o that of no induction (∗P < 0.05, compared to 0g/ml). Results are means
f at least three experiments, and error bars indicate 1 standard deviation
rom the mean. The expression plasmid of-gal (pRSV-gal) as an intrin-
ic control. (B) Dose response of Dox on the induction of p16 expression.
et-on-LMP1-HNE2 cells were treated with 0, 0.006, 0.06, 0.6, 6g/ml
f Dox, as a control without Dox induction at every dose. Cellular protein
100g) was subjected to electrophoresis on 15% SDS-polyacrylamide gel
nd Western blot analysis. P16 is identified by probing with a specific anti-
ody described in Section2. Signals were normalized using expression of
-tubulin as control. (C) Time course of p16 expression with induction of
.6g/ml of Dox. Tet-on-LMP1-HNE2 cells were treated with 0.6g/ml of
ox, as a control without Dox induction at every time point. Cellular pro-
ein (100g) was subjected to electrophoresis on 15% SDS-polyacrylamide
el and Western blot analysis. p16 is identified by probing with a specific
ntibody described in Section2. Signals were normalized using expression
f -tubulin as control.
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Table 1
Cell cycle distribution (%) of Tet-on-LMP1-HNE2 cells treated with 0.6g/ml Dox at the different time points
Phases Time points (h)
0 0.5 1 2 4 8 12 18 24
Dox(−)/G1 55.8 53.9 53.1 49.2 41.7 48 57.8 65.7 66.3
Dox(+)/G1 55.8 57.7 55.1 52.5 42.4 52.2 58 70.2 74.1
Dox(−)/S 40.8 43.2 43.7 48.9 52.1 40.6 29.5 24.1 26.4
Dox(+)/S 40.8 40.2 42.6 46 51.8 36.5 28.6 20.9 21.7
Dox(−)/G2 3.4 2.9 3.2 1.9 8.7 11.4 14.5 10.2 7.3
Dox(+)/G2 3.4 2.1 2.3 1.5 5.8 11.3 13.4 8.9 4.2
increased in a time-dependent manner, while a c-Jun/Jun B
heterodimer increased gradually, then decreased after 18 h
(Song et al., 2004). To further confirm the c-Jun/Jun B het-
erodimer accelerated by LMP1 regulated cyclin D1 protein
expression, Western blot analyses were performed at the dif-
ferent time points. Results demonstrated that cyclin D1 ex-
pression increased form 0.5 h, maintaining at higher level
up to 8 h, decreasing from 12 h and extremely weak at 24 h
(Fig. 4C).
In the same condition, also, data showed that p16 promot-
ers activity and its protein expression decreased gradually
(Fig. 5).
3.3. Effects of LMP1 encoded by EBV on cell cycle by
inducing a c-Jun/Jun B heterodimer modulating cyclin
D1 and p16 expression directly and synchronously
Cyclin D1 and p16 is, respectively, regarded as key posi-
tive and negative modulators of network of cell cycle (Sarasin,
2003). Based on LMP1 inducing a c-Jun/Jun B heterodimer
formation (Song et al., 2004), and then upregulating cyclin
D1 (Fig. 4), while downregulating p16 promoters activity and
expression (Fig. 5), we further explored the effects of the cy-
clin D1 and p16 cooperatively on cell cycle at the different
time points.





almost every time point in the G1 phase ascended at some de-
gree, and meanwhile descending in S and G2 phases (Table 1,
Fig. 6A). This suggested the cells traverse through the cell cy-
cle more quickly in the presence of LMP1 with the induction
of Dox.
To further elucidate the relativity between cell percent-
age and cyclin D1 and p16 expression in the time-course, the
mean fluorescence intensity of cyclin D1 and p16 was de-
tected by immunocytometry. The results indicated cyclin D1
strengthened significantly only in 0.5 h, kept in a high state
from 0.5 to 8 h, and decreased in evidence from 8 to 24 h
(Table 2, Fig. 6B), while p16 weaked gradually (Table 3,
Fig. 6C). Thus, these results indicates that the mean fluores-
cence intensity of cyclin D1 and p16 matches much ones of
cyclin D1 and p16 at protein level (Figs. 4C and 5C).
4. Discussion
Our late study confirmed that LMP1 induced formation
of active a c-Jun/Jun B heterodimer in Tet-on-LMP1-HNE2
cell line, and the heterodimer could bind to the AP1-DNA-
binding motif (Song et al., 2004).
In this paper, we further found that LMP1 accelerated a
c-Jun/Jun B heterodimer binding, respectively, with the site












D 8 55.89NA content of Tet-on-LMP1-CNE2 cells treated w
.6g/ml Dox was detected in the indicated time points
ow cytometry for determining changes of cell cycle. D
howed that after Dox induction the percentage of cel
able 2
yclin D1 mean fluorescence intensity in the Tet-on-LMP1-HNE2 cel
Time points (h)
0 0.5 1 2
ox(−) 356.34 385.21 381.04 375.8
ox(+) 356.34 370.45 370.99 369.7
able 3
16 mean fluorescence intensity in the Tet-on-LMP1-HNE2 cells trea
Time points (h)
0 0.5 1 2
ox(−) 656.13 635.79 630.63 601.8
ox(+) 656.13 621.89 614.76 590.9n cyclin D1 promoter region (Fig. 2) and the site (5′-
TCTCATTCTGTCACCCAGGC-3′,−530 to−539) in p16
romoter region (Fig. 3), upregulating cyclin D1 (Fig. 4)
hile downregulating p16 promoters activity and protein
d with 0.6g/ml of Dox at the different time points
4 8 12 18 24
376.00 377.83 367.97 350.52 3
370.55 365.89 359.12 348.64 3
0.6g/ml of Dox at the different time points
4 8 12 18 24
569.74 516.72 484.56 473.45 4
555.76 510.57 475.67 461.67 4
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Fig. 6. (A) Distribution (%) of the Tet-on-LMP1-HNE2 cells in the phases
of cell cycle treated with Dox at the different time points, as a control with-
out Dox induction at every time point. Cells were treated with 0.6g/ml
Dox for different time as indicated above. 2× 106 cell were fixed with
ethanol,stained with propidium iodide,and analysized with Becton Dickin-
son flow cytometer. Dead cells were excluded by propidium iodide staining.
The data represent one of three independent experiments performed with
consistent results. In order to give visually the changes (A) was constructed
according to the results inTable 1. (B) The mean fluorescence intensity of
cyclin D1 in the all phases with Dox induction at the different time points in
Tet-on-LMP1-HNE2 cells, as a control without Dox induction at every time
point. Cells were treated with 0.6g/ml Dox for different time as indicated
above. 2× 106 cells were fixed with paraformaldehyde and ethanol,stained
with propidium iodide. Cyclin D1 expression was analyzed by immunos-
taining with anti-cyclin D1 antibody followed by FITC-conjugated anti-
mouse secondary antibody by Becton Dickinson flow cytometry. Dead cells
were excluded by propidium iodide staining. Each staining was performed
at least three times with similar results. (B) was constructed according to
the results inTable 2. (C) The mean fluorescence intensity of p16 with
Dox induction at the different time points in Tet-on-LMP1-HNE2 cells, as
a control without Dox induction at every time point. Cells were treated with
0.6g/ml Dox for different time as indicated above. 2× 106 cell were fixed
with paraformaldehyde and ethanol, stained with propidium iodide. p16 ex-
pression was analyzed by immunostaining with anti-p16 antibody followed
by FITC-conjugated anti-mouse secondary antibody by Becton Dickinson
flow cytometry. Dead cells were excluded by propidium iodide staining.
Each staining was performed at least three times with similar results. (C)
was constructed according to the results inTable 3.
pression (Fig. 5). To be interesting, reasons why cyclin D1
and p16 expression induced by LMP1 shows opposite behav-
ior may lie in the changes of amount of a c-Jun/Jun B het-
erodimer binding to between cyclin D1 and p16 promoter re-
gion, or an increasing c-Jun/Jun B heterodimer binding partly
to enhancer of cyclin D1, while partly to silencer of p16.
Also, many data shows NF-B regulates cyclin D1 expres-
sion and G0/G1-to-S-phase transition of cell cycle by binding
three sites in cyclin D1 promoter region (Hinz et al., 1999;
Guttridge et al., 1999). In the meantime, we also found cross-
talk between AP-1(c-Jun) and NF-B (p50 and p65) signal
pathways (Yang et al., 2003; Delerive et al., 1999; Yin et
al., 2001; Liao et al., 1999a,b; Wang et al., 2003). Thus, in
Tet-on-LMP1-HNE2 cell line, LMP1 may mediate NF-B
and AP1 signal pathways, and integrate signals on cyclin D1
(Deng et al., 2003; Wang et al., 2002), which is involved in
the imbalance of cell proliferation and apoptosis (Zhao et al.,
2000, 2001). Taken together, in some degrees, our data con-
firmed LMP1 modulated cyclin D1 and p16 synchronously
via active a c-Jun/Jun B heterodimer formation.
Between phages of cell cycle, there exist a series of G1/S,
G2/M and, etc. checkpoints, which supervise and modulate
phages of cell cycle to make them normal transition, thus
guarantee cell cycle progress orderly. Especially, G1/S check-
point is vital (Molinari, 2000).































f maladjustment during multistage carcinogenesis, ev
he precancerous phase. This may lie mainly in both p
ive regulator cyclin D1 and negative regulator p16, wh
re closely corelated with the regulation of G1/S checkp
Lukas et al., 1995).
In the physiological state, cyclin D1 expresssion of c
n the logarithmic growth phage peaks in G0 phage with
timulus to mitotic signal. Cyclin D1 appears in G0 and e
1 phages, degrades before cells into S phase and disa
n S and G2/M phages in the most conditions. There
yclin D1 is considered as an important marker of G0
ransition (Tam et al., 1994).
Thus, cyclin D1 is firstly expressed when cell is stimula
nto cell cycle, and cyclin D1 becomes vital tache betw
xtracellular growth factor, signal transduction and cell
le (Arber et al., 1996). Cyclin D1 combines with cyclin
ependent-kinase 4/6 (CDK4/6) into complex and mak
ctive. Then Rb is phosphorylated by active CDK4/6 an
eases E2F, which binds to Rb. E2F enters into cell nuc
nd triggers the expression of downstream target gen
ated to cell cycle, which promote cells overpassing G
heckpoint (Sherr, 1995, 1996; Donjerkovic and Scott, 20
artek et al., 1996). Furthermore, once cells in the cell cy
verpass G1/S checkpoint, there existing in the irrever
tate (Bartek et al., 1999). On the contrary, indolocarbazol
selective inhibitor of cyclin D1/CDK4, could make cells
umor stop growing, blocking in G1 phase (Petty et al., 2003
hu et al., 2003; Engler et al., 2003). Recent study demo
trated transient cyclin D1 expression was sufficient fo
elerating normal reproduction and growth of cells (Nelsen
X. Song et al. / Virus Research 113 (2005) 89–99 97
et al., 2001), but overexpression triggered cell cycle drive
engine strengthening uninterrupted, disorder of G1/S check-
point to make unrepaired cell into next phage, thus leading to
genome more unstable, and quickening up tumor malignant
progression (Robles et al., 1996; Zhou and Elledge, 2000).
But, p16 is regarded as an inhibitor of CDK and negative
regulator of cell cycle G1/S checkpoint, the amino-terminus
of p16 is of the same homogenous domain as of cyclin D1. p16
competes binding sites to CDK with cyclin D1. Obviously,
p16 may prevent G1/S checkpoint from dysfunction, even
carcinogenesis, and counteract CDK overactivation by cyclin
D1 (Sarasin, 2003).
Recently, data demonstrated that p16 could lead cells to
arrest in G0/G1 phase as a inhibitor of CDK in the nasopha-
ryngeal carcinoma (Chow et al., 2000). Lack of p16 made
cell loss of negative control on CDK, resulting in more cells
across G1/S checkpoint, and accelerating cell overgrowth
(Shibosawa et al., 2000).
Also, more data demonstrated that p16 cooperation with
cyclin D1 were critical for growth arrest during mammary
involution (Gadd et al., 2001). The imbalance between p16
and cyclin D1 expression was closely correlated to tumor
progression in bladder cancer (Yang et al., 2002), both inac-
tivation of p16 and overexpression of cyclin D1 was much
related to upper aerodigestive tract, primary oral cancer and
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